Anna M G Pasmooij - Univ Groningen, Univ Med Ctr Groningen

基本信息

浏览量：35

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 108 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting

Eva W. H. Korte,Phyllis Spuls,Peter C. van den Akker,Dimitra Kiritsi,Martin Laimer,Anna M. G. Pasmooij, Rainer Riedl,Elizabeth Vroom,Verena Wally,Tobias Welponer,Maria C. Bolling

BRITISH JOURNAL OF DERMATOLOGYno. 2 (2024): 268-270

引用0浏览0引用

The European Innovation Network as a hub for medicines innovation in Europe

Eleonora Agricola, Caroline Auriche-Benichou, Helena Baiao, Oriane Blanquie, Teodora Bodea, Tomáš Boráň,John-Joseph Borg, Valentina Cordo', Maria Di Marzo, Lars Dmowski Rugholm, Falk Ehmann, Rúna Hauksdóttir Hvannberg,

Nature reviews. Drug discovery (2024)

引用0浏览0WOSNATURE引用

Access to medicines for rare diseases: A European regulatory roadmap for academia

Noa Rosenberg,Sibren van den Berg, Nina N. Stolwijk,Bart A. W. Jacobs, Hendrika C. Post,Anna M. G. Pasmooij,Saco J. de Visser,Carla E. M. Hollak

Front Pharmacol（2023）

引用1浏览0WOS引用

Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization

Eva W. H. Korte,Tobias Welponer,Jan Kottner,Sjoukje van der Werf,Peter C. van den Akker,Barbara Horvath,Dimitra Kiritsi,Martin Laimer,Anna M. G. Pasmooij,Verena Wally,Maria C. Bolling

BRITISH JOURNAL OF DERMATOLOGY（2023）

引用2浏览0WOS引用

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

R. K. Ismail, F. M. N. H. Schramel,M. van Dartel,A. M. G. Pasmooij, C. M. Cramer-van der Welle, D. L. Hilarius,A. de Boer,M. W. J. M. Wouters,E. M. W. van de Garde

BMC Med Res Methodol（2023）

引用1浏览0WOS引用

IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases

Anneliene Hechtelt Jonker,Simon Day,Michela Gabaldo,Heather Stone, Martin de Kort,Daniel J O'Connor,Anna Maria Gerdina Pasmooij

Nature reviews. Drug discoveryno. 12 (2023): 937-938

引用0浏览0WOSNATURE引用

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe

Marko J Kallio,Viktoriia Starokozhko, Eleonora Agricola, Manja Burggraf, Anne Heß,Wolfgang Ballensiefen, Wiebke Löbker,Yoana Nuevo,Anna M G Pasmooij,Peter G M Mol

Clinical pharmacology and therapeuticsno. 2 (2023): 349-359

引用4浏览0WOS引用

The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies

Katherine L Beaverson, Daria Julkowska,Mary Catherine V Letinturier,Annemieke Aartsma-Rus,Jennifer Austin,Juan Bueren, Simon Frost, Misako Hamamura, Jane Larkindale,Greg LaRosa, Rita Magenheim,Annamaria Merico,

Therapeutic advances in rare disease (2023): 26330040231188979

引用0浏览0WOS引用

Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study

Marijn Muurling,Anna M G Pasmooij,Ivan Koychev,Dora Roik,Lutz Froelich,Emilia Schwertner,Dorota Religa,Carla Abdelnour,Mercè Boada,Monica Almici,Samantha Galluzzi,Sandra Cardoso,

PloS oneno. 7 (2023): e0285807-e0294797

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn